Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizer Dashes Hopes For A PCSK9 Pill

Executive Summary

Pfizer has decided not to move forward with an oral PCSK9 blocker in early clinical development because the efficacy wouldn’t stand up to injectable rivals.

Advertisement

Related Content

What To Look Out For At ACC
Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s
A Split Won’t “Make Or Break” Pfizer, CEO Read Says
Pfizer inSPIREd By Late-Stage PCSK9 Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel